RLAY VS ANIP Stock Comparison
Performance
RLAY10/100
10/100
RLAY returned -58.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
ANIP100/100
100/100
ANIP returned 45.01% in the last 12 months. Based on SPY's performance of 9.73%, its performance is above average giving it a score of 100 of 100.
Technicals
RLAY64/100
64/100
RLAY receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
ANIP32/100
32/100
ANIP receives a 32 of 100 based on 14 indicators. 4 are bullish, 9 are bearish.
Earnings
RLAY10/100
10/100
RLAY has missed earnings 8 times in the last 20 quarters.
ANIP17/100
17/100
ANIP has missed earnings 6 times in the last 20 quarters.
Profit
RLAY10/100
10/100
Out of the last 19 quarters, RLAY has had 1 profitable quarters and has increased their profits year over year on 1 of them.
ANIP37/100
37/100
Out of the last 20 quarters, ANIP has had 9 profitable quarters and has increased their profits year over year on 4 of them.
Volatility
RLAY53/100
53/100
RLAY has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.
ANIP43/100
43/100
ANIP has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.
Analyst Price Targets
RLAY
"Analyst Price Targets" not found for RLAY
ANIP83/100
83/100
3 analysts offer 12-month price targets for ANIP. Together, they have an average target of 48, the most optimistic target put ANIP at 48 within 12-months and the most pessimistic has ANIP at 48.
Sentiment
RLAY
"Sentiment" not found for RLAY
ANIP69/100
69/100
ANIP had a bullish sentiment score of 68.80% across Twitter and StockTwits over the last 12 months. It had an average of 6.60 posts, 1.00 comments, and 1.00 likes per day.
Dividend
RLAY
"Dividend" not found for RLAY
ANIP10/100
10/100
ANIP's most recent dividend was $0.01 per share, based on a share price of $53.22. It was a payout ratio of -0.78% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
Relay Therapeutics, Inc. Common Stock Summary
Nasdaq / RLAY
Healthcare
Biotechnology
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
ANI Pharmaceuticals, Inc. Summary
Nasdaq / ANIP
Healthcare
Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare RLAY to other companies in the same or a similar industry.